#AASLD26: Merck unwraps biopsy data for MASH drug it got from South Korea's Hanmi

Merck reported Thursday its dual GLP-1/glucagon agonist cleared a mid-stage trial in the liver disease called MASH, sharing biopsy data on a drug it licensed from Hanmi Pharmaceutical in 2020 for $10 ...